NCT00571584 - High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

March 31, 2004

Study Completion Date

March 31, 2004

Conditions

Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors

Interventions

DRUG

activated recombinant human factor VII

Trial Locations (18)

1135

Novo Nordisk Investigational Site, Budapest

28046

Novo Nordisk Investigational Site, Madrid

35100

Novo Nordisk Investigational Site, Bornova-IZMIR

Novo Nordisk Investigational Site, Capa-ISTANBUL

46026

Novo Nordisk Investigational Site, Valencia

52621

Novo Nordisk Investigational Site, Tel Litwinsky

59037

Novo Nordisk Investigational Site, Lille

69003

Novo Nordisk Investigational Site, Lyon

75014

Novo Nordisk Investigational Site, Paris

75015

Novo Nordisk Investigational Site, Paris

94270

Novo Nordisk Investigational Site, Le Kremlin-Bicêtre

61-833

Novo Nordisk Investigational Site, Poznan

00-576

Novo Nordisk Investigational Site, Warsaw

00-791

Novo Nordisk Investigational Site, Warsaw

50-345

Novo Nordisk Investigational Site, Wroclaw

B15 2TH

Novo Nordisk Investigational Site, Birmingham

Unknown

Novo Nordisk Investigational Site, Canterbury

S10 2JF

Novo Nordisk Investigational Site, Sheffield